Filing Flows › DexCom (DXCM) › Q3 2026 › vs Q2 2026
DexCom (DXCM) Q3 2026 vs Q2 2026 (quarter over quarter)
DexCom's revenue rose $36.1M (+3%) from $1.3B in Q2 2026 to $1.3B in Q3 2026. Gross margin 64.3% against 63.4% (+0.9 pts).
DexCom, Q3 2026: revenue $1.3B (+11% year over year), operating margin 24.3%, net earnings $275M, operating cash flow $326M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 64.3% | 63.4% | +0.9 pts |
| Operating margin | 24.3% | 24.3% | +0.0 pts |
| Net margin | 20.5% | 19.0% | +1.4 pts |
| Free cash flow margin | 20.3% | 14.1% | +6.2 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $1.3B | $1.3B | $36.1M | +3% |
| Gross profit | $864M | $830M | $34.4M | +4% |
| Cost of revenue | $480M | $478M | $1.7M | +0.4% |
| Other income, net | $7.5M | −$800K | $8.3M | — |
| Operating profit | $327M | $318M | $8.9M | +3% |
| Operating expenses | $537M | $512M | $25.5M | +5% |
| Pre-tax earnings | $335M | $318M | $17.2M | +5% |
| Research & development | $162M | $153M | $8.6M | +6% |
| SG&A | $376M | $359M | $16.9M | +5% |
| Net earnings | $275M | $249M | $26.0M | +10% |
| Income tax | $59.6M | $68.4M | −$8.8M | -13% |
| Depreciation & amortization | $74.5M | $68.2M | $6.3M | +9% |
| Share-based compensation | $36.8M | $39.0M | −$2.2M | -6% |
| Working capital & other | $60.8M | $87.1M | −$26.3M | -30% |
| Operating cash flow | $326M | $269M | $56.4M | +21% |
| Free cash flow (OCF − capex) | $273M | $184M | $88.2M | +48% |
| Capital expenditures | $52.9M | $84.7M | −$31.8M | -38% |
Questions
How much did DexCom's revenue grow quarter over quarter in Q3 2026?
DexCom's revenue rose $36.1M (+3%) from $1.3B in Q2 2026 to $1.3B in Q3 2026. Gross margin 64.3% against 63.4% (+0.9 pts).